- Kindeva to double UK lab space, enhancing green propellant production.
- Relocation of 50 quality control staff to new site, with potential for further expansion.
Kindeva Drug Delivery is set to expand its facilities at the Charnwood Campus Science Innovation and Technology Park in Loughborough, UK. The expansion aims to support the commercialisation of green propellant technologies and provide a new home for the company’s commercial analytical lab services team.
The expansion will effectively double Kindeva’s laboratory footprint in the UK, broadening its operational capabilities. Approximately 50 quality control employees will be transferred from Kindeva’s existing Loughborough manufacturing site to the new location. The company has also announced the addition of a second manufacturing line dedicated to the production of pressurized metered-dose inhaler (pMDI) products that utilize low Global Warming Potential (GWP) propellants.
Carl Brookes, Vice President of Manufacturing and Operations – Loughborough at Kindeva, commented on the expansion, stating, “This expansion is one more step in furthering the commercialization of our customers’ low GWP pMDI products. It’s an exciting time for green propellants, and we are committed to remaining at the forefront of these product transitions supporting a greener planet.”